Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer
- 29 May 2015
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (1) , e1049802
Abstract
Interleukin-6, a cytokine produced particularly by triple-negative breast cancers, strongly inhibits T cell responses in the tumor microenvironment. Here we tested cryoablation combined with Meriva (a lecithin delivery system of curcumin with improved bioavailability) in mice with metastatic breast cancer (4T1). Cryoablation involves killing of tumor cells through freezing and thawing, resulting in recruitment of tumor-specific T cells, while curcumin stimulates T cells through the reduction of IL-6 in the TME. Cryoablation plus Meriva accumulated and activated CD8+ T cells to multiple tumor-associated antigens such as Mage-b and Survivin (both expressed by 4T1 tumors). This correlated with a nearly complete reduction of 4T1 primary tumors and lung metastases while little effect was observed from saline or Meriva alone (28 d after tumor cell injection). The survival rate in the group of cryoablation plus Meriva was significantly improved compared to all control groups. Using a less aggressive 4T1 model expressing luciferase (4T1.2luc3), we demonstrated that all mice receiving saline or Meriva developed metastases in the lungs and a primary tumor (38 d after tumor cell injection; and died soon after that), but not the mice receiving cryoablation or cryoablation plus Meriva. However, on day 58 the mice receiving cryoablation developed 4T1.2luc3 metastases in the lungs, while mice receiving cryoablation plus Meriva were free of metastases. These results strongly suggest that cryoablation delayed the development of lung metastases on the short-term, but Meriva administered after cryoablation was significantly better in delaying the development of lung metastases and survival on the long-term.Keywords
This publication has 42 references indexed in Scilit:
- CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcomeHuman Pathology, 2012
- Interleukin-6 - A Key Regulator of Colorectal Cancer DevelopmentInternational Journal of Biological Sciences, 2012
- Interleukin-6 as a Therapeutic Target in Human Ovarian CancerClinical Cancer Research, 2011
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumorsJournal of Clinical Investigation, 2011
- Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinomaMolecular Cancer, 2011
- Targeting Breast Cancer Stem CellsJournal of Clinical Oncology, 2010
- The therapeutic promise of the cancer stem cell conceptJournal of Clinical Investigation, 2010
- The Increasing Complexity of the Cancer Stem Cell ParadigmScience, 2009
- Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastasesBritish Journal of Cancer, 2008
- IL-6 involvement in epithelial cancersJournal of Clinical Investigation, 2007